Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells.

Landrette SF, Madera D, He F, Castilla LH.

Leukemia. 2011 Apr;25(4):655-62. doi: 10.1038/leu.2010.301. Epub 2011 Jan 25.

2.

Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.

Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH.

Blood. 2012 Jul 26;120(4):868-79. doi: 10.1182/blood-2012-03-414649. Epub 2012 May 21.

3.

The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.

Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC.

Blood. 2012 Jul 26;120(4):709-19. doi: 10.1182/blood-2012-01-403212. Epub 2012 Feb 14.

4.

Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11.

Landrette SF, Kuo YH, Hensen K, Barjesteh van Waalwijk van Doorn-Khosrovani S, Perrat PN, Van de Ven WJ, Delwel R, Castilla LH.

Blood. 2005 Apr 1;105(7):2900-7. Epub 2004 Dec 7.

5.

Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.

Heller PG, Glembotsky AC, Gandhi MJ, Cummings CL, Pirola CJ, Marta RF, Kornblihtt LI, Drachman JG, Molinas FC.

Blood. 2005 Jun 15;105(12):4664-70. Epub 2005 Mar 1.

6.

Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.

Kalina U, Hofmann WK, Koschmieder S, Wagner S, Kauschat D, Hoelzer D, Ottmann OG.

Exp Hematol. 2000 Oct;28(10):1158-63.

PMID:
11027834
7.

Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.

Nishikawa S, Arai S, Masamoto Y, Kagoya Y, Toya T, Watanabe-Okochi N, Kurokawa M.

Blood. 2014 Dec 4;124(24):3587-96. doi: 10.1182/blood-2013-12-546275. Epub 2014 Oct 8.

8.

Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways.

Doshi PD, Giri JG, Abegg AL, Favara JP, Huynh MS, Kahn LE, Minnerly JC, Pegg LE, Villani-Price D, Siegel NR, Staten NR, Thomas JW, McKearn JP, Smith WG.

Exp Hematol. 2001 Oct;29(10):1177-84.

PMID:
11602319
9.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

10.

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Köhler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H.

Mol Cell Biol. 2004 Apr;24(7):2890-904.

11.

Identification and characterization of an alternative splice variant of Mpl with a high affinity for TPO and its activation of ERK1/2 signaling.

Wang Q, Sun R, Wu L, Huang J, Wang P, Yuan H, Qiu F, Xu X, Wu D, Yu Y, Liu X, Zhang Q.

Int J Biochem Cell Biol. 2013 Dec;45(12):2852-63. doi: 10.1016/j.biocel.2013.09.010. Epub 2013 Oct 19.

PMID:
24144576
12.

NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.

Xue L, Pulikkan JA, Valk PJ, Castilla LH.

Blood. 2014 Jul 17;124(3):426-36. doi: 10.1182/blood-2013-12-541730. Epub 2014 Jun 3.

13.

Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice.

Kuo YH, Zaidi SK, Gornostaeva S, Komori T, Stein GS, Castilla LH.

Blood. 2009 Apr 2;113(14):3323-32. doi: 10.1182/blood-2008-06-162248. Epub 2009 Jan 28.

14.

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM.

Blood. 2012 Oct 4;120(14):2843-52. doi: 10.1182/blood-2012-02-413021. Epub 2012 Aug 17.

15.

Thrombopoietin activates a STAT5-like factor in hematopoietic cells.

Pallard C, Gouilleux F, Bénit L, Cocault L, Souyri M, Levy D, Groner B, Gisselbrecht S, Dusanter-Fourt I.

EMBO J. 1995 Jun 15;14(12):2847-56.

16.

Membrane localization is not required for Mpl function in normal hematopoietic cells.

Otto KG, Broudy VC, Lin NL, Parganas E, Luthi JN, Drachman JG, Ihle JN, Blau CA.

Blood. 2001 Oct 1;98(7):2077-83.

17.

The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1.

de la Luz Sierra M, Sakakibara S, Gasperini P, Salvucci O, Jiang K, McCormick PJ, Segarra M, Stone J, Maric D, Zhu J, Qian X, Lowy DR, Tosato G.

Blood. 2010 May 13;115(19):3970-9. doi: 10.1182/blood-2009-10-246967. Epub 2010 Mar 4.

18.
19.

Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development.

Li H, Ji M, Klarmann KD, Keller JR.

Blood. 2010 Aug 19;116(7):1060-9. doi: 10.1182/blood-2009-11-255075. Epub 2010 May 7.

20.

Inhibition of Thrombopoietin/Mpl Signaling in Adult Hematopoiesis Identifies New Candidates for Hematopoietic Stem Cell Maintenance.

Kohlscheen S, Wintterle S, Schwarzer A, Kamp C, Brugman MH, Breuer DC, Büsche G, Baum C, Modlich U.

PLoS One. 2015 Jul 6;10(7):e0131866. doi: 10.1371/journal.pone.0131866. eCollection 2015.

Supplemental Content

Support Center